Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAID-II: Adrenergic blockade during hypoglycaemia-induced inflammation in type 1 diabetes and healthy participants
NL-OMON57053Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of human insulin in diabetes mellitus type 1 (T1D) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Effect of adrenergic inhibition on hypoglycaemia-induced inflammatory response. Started Jan 2025; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON57053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57053.